Precis Future Med Search

CLOSE


Best Practice

  • HOME
  • ABOUT
  • Best Practice

As an open access journal, Clinics in Shoulder and Elbow (CiSE) will follow the Principles of Transparency and Best Practice in Scholarly Publishing (https://doaj.org/bestpractice) developed by Committee on Publication Ethics (COPE), the Directory of Open Access Journals (DOAJ), the Open Access Scholarly Publishers Association (OASPA), and the World Association of Medical Editors (WAME).

Table of Contents

1. Website

The URL address of official journal web site is https://www.pfmjournal.org.

The Precision and Future Medicine (P&FM) team endeavors to make a good website. P&FM website demonstrates that care has been taken to ensure high ethical and professional standards. It does not contain any misleading information, including any attempt to mimic another journal/publisher’s site.

Aims & Scope statement: https://www.pfmjournal.org/about/
Authorship criteria: https://www.pfmjournal.org/authors/authors.php
ISSN Information:pISSN: 2508-7940     eISSN: 2508-7959

2. Name of journal

The official journal title is Precision and Future Medicine (P&FM). Abbreviated title is Precis Future Med.

3. Peer review process

https://www.pfmjournal.org/authors/authors.php#e5

Type of peer review: Double-blind review

Method of peer review
All submitted manuscripts are screened for duplication through Crosscheck (https://app.ithenticate.com) before review. P&FM reviews all manuscripts received. A manuscript is first reviewed for its format and then sent to the two most relevant investigators of the field. In addition, if deemed necessary, a review of the manuscript’s statistics may be requested. Authors’ names and affiliations are removed during peer review. The acceptance criteria for all papers are based on the quality and the originality of the research and its clinical and scientific significance. Acceptance of the manuscript is decided on the basis of the critiques and the recommended decision of the referees. An initial decision will normally be made within 4 weeks of receipt of a manuscript and the reviewers’comments sent to the corresponding authors by e-mail. Revised manuscripts must be submitted online by the corresponding author. The corresponding author must indicate the alterations that have been made in response to the referees’ comments item by item. Failure to resubmit the revised manuscript within 4 weeks of the editorial decision is regarded as a withdrawal. A final decision on acceptance for publication or rejection for publication is forwarded to the corresponding author from the Editorial Office.
Any appeal against the editorial decision must be made within 2 weeks of the date on the decision letter. Authors who wish to appeal a decision should contact the Editor-in-Chief, explaining in detail their reasons for the appeal. All appeals will be discussed with at least one other associate editor. If the associate editor(s) does not agree, the appeal will be discussed at a full editorial meeting. P&FM does not consider second appeals.

4. Ownership, journal management team, and publishing credentials

The journal is owned by the publisher, the Sungkyunkwan University School of Medicine. http://www.skkumed.ac.kr/eng/

The management team is as follows:

- Journal Manager: Oh Young Bang, Editor-in-Chief, Sungkyunkwan University School of Medicine, Korea
- Managers of the Review Process:
          Han-Sin Jeong, Sungkyunkwan University School of Medicine, Korea
          Tae Jung Kim, Sungkyunkwan University School of Medicine, Korea
- Ethics Editor: Wenyu Li, Medical School of Zhejiang University, China
- Statistics Editor: Seonwoo Kim, Sungkyunkwan University School of Medicine, Korea
- Manuscript Editor: Young Ji Choi, InfoLumi, Korea
- English Editor: Editage, Korea
- Layout Editor: Soo Bin Han, Academya, Korea
- Website and JATS XML Producer: Jeonghee Im, M2PI, Korea
- Editorial Assistant: Sungkyunkwan University School of Medicine, Korea

5. Governing body

The governing body is the journal's editorial board.

6. Editorial team and contact information

https://www.pfmjournal.org/about/editorial.php

The Editorial team is available from Editorial Board page at the front part of the journal.

Contact information
Editor-in-Chief: Oh Young Bang, MD, PhD., Sungkyunkwan University School of Medicine, Korea

Editorial Office: Sungkyunkwan University School of Medicine
115 Irwon-ro, Gangnam-gu, Seoul 06355, Korea
Tel: +82-2-3410-6939
Fax: +82-2-2148-9919
E-mail: pfmjournal@skku.edu

7. Copyright and licensing

Copyright policy: All published papers become the permanent property of the Sungkyunkwan University School of Medicine. Copyrights of all published materials are owned by the Sungkyunkwan University School of Medicine and permission must be obtained for any commercial use of materials. Every author should sign the copyright transfer agreement forms.

Licensing information: This is an Open Access journal distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

8. Author fees

https://www.pfmjournal.org/authors/charge.php

There are no author submission fees or other publication-related charges. All cost for the publication process is supported by the Publisher. P&FM is a so-called platinum open access journal which does not charge author fees.

9. Process for the identification of and dealing with allegations of research misconduct

https://www.pfmjournal.org/authors/ethics.php

When the journal faces suspected cases of research and publication misconduct such as redundant (duplicate) publication, plagiarism, fraudulent or fabricated data, changes in authorship, an undisclosed conflict of interest, ethical problems with a submitted manuscript, a reviewer who has appropriated an author’s idea or data, complaints against editors, and so on, the resolution process will follow the flowchart provided by the Committee on Publication Ethics (COPE) (http://publicationethics.org/resources/flowcharts). The discussion and decision on the suspected cases are carried out by the Editorial Board.

10. Publication ethics

Journal policies on authorship and contributorship

https://www.pfmjournal.org/authors/ethics.php

Authorship credit should be based on 1) substantial contributions to conception and design, acquisition of data, and/or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; 3) final approval of the version to be published; and 4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Every author should meet all of these four conditions. After the initial submission of a manuscript, any changes whatsoever in authorship (adding author(s), deleting author(s), or re-arranging the order of authors) must be explained by a letter to the editor from the authors concerned. This letter must be signed by all authors of the paper. Copyright assignment must also be completed by every author.

Corresponding author and first author: Precision and Future Medicine does not allow multiple corresponding authors for one article. Only one author should correspond with the editorial office and readers for one article. Precision and Future Medicine does accept notice of equal contribution for the first author when the study was clearly performed by co-first authors.

Correction of authorship after publication: Precision and Future Medicine does not correct authorship after publication unless a mistake has been made by the editorial staff. Authorship may be changed before publication but after submission when an authorship correction is requested by all of the authors involved with the manuscript.

How the journal will handle complaints and appeals
The policy of the journal is primarily aimed at protecting the authors, reviewers, editors, and the publisher of the journal. If not described below, the process of handling complaints and appeals follows the COPE guidelines available from: https://publicationethics.org/appeals.

Who complains or makes an appeal? Submitters, authors, reviewers, and readers may register complaints and appeals in a variety of cases as follows: falsification, fabrication, plagiarism, duplicate publication, authorship dispute, conflict of interest, ethical treatment of animals, informed consent, bias or unfair/inappropriate competitive acts, copyright, stolen data, defamation, and legal problem. If any individuals or institutions want to inform the cases, they can send a letter via the contact page on our website: https://www.pfmjournal.org/about/contact.php. For the complaints or appeals, concrete data with answers to all factual questions (who, when, where, what, how, why) should be provided.

Who is responsible for resolving and handling complaints and appeals? The Editor, Editorial Board, or Editorial Office is responsible for them. A legal consultant or ethics editor may be able to help with decision making.

What may be the consequence of the remedy? It depends on the type or degree of misconduct. The consequence of resolution will follow the COPE guidelines.

Journal policies on conflicts of interest / competing interests
The corresponding author must inform the editor of any potential conflicts of interest that could influence the authors’ interpretation of the data. Examples of potential conflicts of interest are financial support from or connections to companies, political pressure from interest groups, and academically related issues. In particular, all sources of funding applicable to the study should be explicitly stated.

Journal policies on data sharing and reproducibility;

https://www.pfmjournal.org/authors/ethics.php

This journal follows the data sharing policy described in "Data Sharing Statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors" (https://doi.org/10.3346/jkms.2017.32.7.1051). As of July 1, 2018 manuscripts submitted to ICMJE journals that report the results of interventional clinical trials must contain a data sharing statement as described below. Clinical trials that begin enrolling participants on or after January 1, 2019 must include a data sharing plan in the trial's registration. The ICMJE's policy regarding trial registration is explained at http://www.icmje.org/about-icmje/faqs/clinical-trials-registration/. If the data sharing plan changes after registration this should be reflected in the statement submitted and published with the manuscript, and updated in the registry record.
All of the authors of research articles that deal with interventional clinical trials must submit data sharing plan of example 1 to 4 in Table 1. Based on the degree of sharing plan, authors should deposit their data after de-identification and report the DOI of the data and the registered site.

Table 1.   Examples of data sharing statements that fulfill these ICMJE requirements*

Element Example 1 Example 2 Example 3 Example 4
Will individual participant data be available (including data dictionaries)? Yes Yes Yes No
What data in particular will be shared? All individual participant data collected during the trial, after deidentification. Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices). Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices). Not available
What other documents will be available? Study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code Study protocol, statistical analysis plan, analytic code Study protocol Not available
When will data be available (start and end dates)? Immediately following publication. No end date. Beginning at 3 months and ending at 5 years following the article publication. Beginning at 9 months and ending at 36 months following the article publication. Not applicable
With whom? Anyone who wishes to access the data. Researchers who provide a methodologically sound proposal. Investigators whose proposed use of the data has been approved by an independent review committee (“learned intermediary”) identified for this purpose. Not applicable
For what types of analyses? Any purpose To achieve aims in the approved proposal. For individual participant data meta-analysis. Not applicable
By what mechanism will data be made available? Data are available indefinitely at (link to be included). Proposals should be directed to xxx@yyy. To gain access, data requestors will need to sign a data access agreement. Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in our University's data warehouse but without investigator support other than deposited metadata. Not applicable
Data are available for 5 years at a third-party website (link to be included). Information regarding submitting proposals and accessing data may be found at (link to be provided).

ICMJE = International Committee of Medical Journal Editors.
*These examples are meant to illustrate a range of, but not all, data sharing options.

Journal's policy on ethical oversight
When the Journal faces suspected cases of research and publication misconduct such as a redundant (duplicate) publication, plagiarism, fabricated data, changes in authorship, undisclosed conflicts of interest, an ethical problem discovered with the submitted manuscript, a reviewer who has appropriated an author’s idea or data, complaints against editors, and other issues, the resolving process will follow the flowchart provided by COPE (http://publicationethics.org/resources/flowcharts). The Editorial Board will discuss the suspected cases and reach a decision. We will not hesitate to publish errata, corrigenda, clarifications, retractions, and apologies when needed.
Upon discovery of misconduct in research and/or publication ethics, the following actions will be taken: A declaration of manuscript retraction and its reason will be made public via the journal and website and the incident will be shared with the funding agency as applicable, as well as the authors’ institution. A written warning will be issued to authors, who will be banned from submitting manuscripts for a minimum of 3 years. Authors’ membership to the Sungkyunkwan University School of Medicine will also be cancelled.

Journal's policy on intellectual property
All published papers become the permanent property of the Sungkyunkwan University School of Medicine. Copyrights of all published materials are owned by the School.

Journal's options for post-publication discussions and corrections
The post-publication discussion is available through ‘Letter to the Editor’. If any readers have a concern on any articles published, they can submit letters to the editor on the articles. If any errors or mistakes in the article are found, it can be corrected through errata, corrigenda, or retraction.

11. Publishing schedule

The Precision and Future Medicinewill be published four times per year: March 31st, June 30th, September 30th, and December 31st.

12. Access

Precision and Future Medicine is available free in electronic form at http://pfmjournal.org. All articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

There are no author submission fees or other publication-related charges. All cost for the publication process is supported by the Publisher. P&FM is a so-called platinum open access journal which does not charge author fees.

13. Archiving

Full text of Precision and Future Medicine has been archived in National Library of Korea (http://www.nl.go.kr). According to the deposit policy (self-archiving policy) of Sherpa/Romeo (http://www.sherpa.ac.uk), authors cannot archive pre-print (i.e., pre-refereeing), but they can archive post-print (i.e., final draft post-refereeing). Authors can archive publisher's version/PDF.

14. Revenues sources

Revenue sources of journal are from the support of publisher (Sungkyunkwan University School of Medicine).

15. Advertising

Precision and Future Medicine does not accept any commercial product advertisements until policy changes otherwise.

16. Direct marketing

Journal propagation has been done through the journal web site and distribution of an introduction pamphlet. Invitations to submit a manuscript are usually focused on the presenters at conferences, seminars, or workshops if the topic is related to the journal's aims and scope.





ABOUT
ARTICLES

Browse all articles >

ISSUES
TOPICS

Browse all articles >

EDITORIAL
POLICY
AUTHOR
INFORMATION
Editorial Office
Sungkyunkwan University School of Medicine
115 Irwon-ro, Gangnam-gu, Seoul 06355, Korea
Tel: +82-2-3410-6939    Fax: +82-2-2148-9919    E-mail: pfmjournal@skku.edu                

Copyright © 2021 by Sungkyunkwan University School of Medicine.

Developed in M2PI

Close layer
prev next